A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

NCT00482079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

743

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type II

Interventions

DRUG: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks
DRUG: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

Sponsor

Merck Sharp & Dohme LLC